{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T15:50:17Z","timestamp":1788364217803,"version":"build-2803163510"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T00:00:00Z","timestamp":1737590400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T00:00:00Z","timestamp":1737590400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["5R01DA058024"],"award-info":[{"award-number":["5R01DA058024"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-025-55945-4","type":"journal-article","created":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T10:03:52Z","timestamp":1737626632000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Development and preclinical testing of a naloxone prodrug depot for extended protection against opioid overdose"],"prefix":"10.1038","volume":"16","author":[{"given":"Hala","family":"Aldawod","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arjun D.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rasha","family":"Emara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9898-1836","authenticated-orcid":false,"given":"Dengpan","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua S.","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9093-4856","authenticated-orcid":false,"given":"Toufiq Ul","family":"Amin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Md Tariqul Haque","family":"Tuhin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4221-9433","authenticated-orcid":false,"given":"Abdulmalek","family":"Balgoname","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avishan","family":"Kiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jumana M.","family":"Ajlouny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie A.","family":"Felmlee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miki S.","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhaskara R.","family":"Jasti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William K.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5896-3905","authenticated-orcid":false,"given":"James A.","family":"Uchizono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4325-7044","authenticated-orcid":false,"given":"Mamoun M.","family":"Alhamadsheh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,23]]},"reference":[{"key":"55945_CR1","unstructured":"National Institute on Drug Abuse. Drug overdose death rates. https:\/\/nida.nih.gov\/research-topics\/trends-statistics\/overdose-death-rates (2024)."},{"key":"55945_CR2","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1056\/NEJMp2312084","volume":"390","author":"J Friedman","year":"2024","unstructured":"Friedman, J. & Hadland, S. E. The overdose crisis among U.S. adolescents. N. Engl. J. Med. 390, 97\u2013100 (2024).","journal-title":"N. Engl. J. Med."},{"key":"55945_CR3","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1056\/NEJMra1202561","volume":"367","author":"EW Boyer","year":"2012","unstructured":"Boyer, E. W. Management of opioid analgesic overdose. N. Engl. J. Med. 367, 146\u2013155 (2012).","journal-title":"N. Engl. J. Med."},{"key":"55945_CR4","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1002\/cpt.2098","volume":"109","author":"CP France","year":"2021","unstructured":"France, C. P. et al. Countermeasures for preventing and treating opioid overdose. Clin. Pharmacol. Ther. 109, 578\u2013590 (2021).","journal-title":"Clin. Pharmacol. Ther."},{"key":"55945_CR5","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1021\/acsptsci.1c00168","volume":"4","author":"AJ Kassick","year":"2021","unstructured":"Kassick, A. J. et al. Covalently loaded naloxone nanoparticles as a long-acting medical countermeasure to opioid poisoning. ACS Pharmacol. Transl. Sci. 4, 1654\u20131664 (2021).","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"55945_CR6","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-43126-0","volume":"14","author":"PT Bremer","year":"2023","unstructured":"Bremer, P. T., Burke, E. L., Barrett, A. C. & Desai, R. I. Investigation of monoclonal antibody CSX-1004 for fentanyl overdose. Nat. Commun. 14, 7700 (2023).","journal-title":"Nat. Commun."},{"key":"55945_CR7","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1124\/jpet.120.000387","volume":"377","author":"VM Jimenez Jr.","year":"2021","unstructured":"Jimenez, V. M. Jr., Castaneda, G. & France, C. P. Methocinnamox reverses and preventsfentanyl-Induced ventilatory depression in rats. J. Pharmacol. Exp. Ther. 377, 29\u201338 (2021).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"55945_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2021.121326","volume":"611","author":"M Voronkov","year":"2022","unstructured":"Voronkov, M. et al. Modifying naloxone to reverse fentanyl-induced overdose. Int. J. Pharm. 611, 121326 (2022).","journal-title":"Int. J. Pharm."},{"key":"55945_CR9","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.resp.2011.10.009","volume":"180","author":"M Wallisch","year":"2012","unstructured":"Wallisch, M. et al. Naloxone pro-drug rescues morphine induced respiratory depression in Sprague-Dawley rats. Respir. Physiol. Neurobiol. 180, 52\u201360 (2012).","journal-title":"Respir. Physiol. Neurobiol."},{"key":"55945_CR10","doi-asserted-by":"publisher","first-page":"5016","DOI":"10.1016\/j.bmcl.2009.07.061","volume":"19","author":"B Huang","year":"2009","unstructured":"Huang, B. et al. Human plasma-mediated hypoxic activation of indolequinone-based naloxone pro-drugs. Bioorg. Med. Chem. Lett. 19, 5016\u20135020 (2009).","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"55945_CR11","doi-asserted-by":"publisher","first-page":"10545","DOI":"10.1021\/acs.nanolett.3c03426","volume":"23","author":"W Zhang","year":"2023","unstructured":"Zhang, W. et al. On-demand opioid effect reversal with an injectable light-triggered polymer-naloxone conjugate. Nano Lett. 23, 10545\u201310553 (2023).","journal-title":"Nano Lett."},{"key":"55945_CR12","doi-asserted-by":"publisher","first-page":"9992","DOI":"10.1073\/pnas.1300761110","volume":"110","author":"SC Penchala","year":"2013","unstructured":"Penchala, S. C. et al. AG10 inhibits amyloidogenesis and cellular toxicity of the familial amyloid cardiomyopathy-associated V122I transthyretin. Proc. Natl. Acad. Sci. USA 110, 9992\u20139997 (2013).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"55945_CR13","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1056\/NEJMoa2305434","volume":"390","author":"JD Gillmore","year":"2024","unstructured":"Gillmore, J. D. et al. Efficacy and safety of acoramidis in transthyretin amyloid cardiomyopathy. N. Engl. J. Med. 390, 132\u2013142 (2024).","journal-title":"N. Engl. J. Med."},{"key":"55945_CR14","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.2165\/00003495-200161110-00007","volume":"61","author":"K McKeage","year":"2001","unstructured":"McKeage, K. & Goa, K. L. Insulin glargine: a review of its therapeutic use as a long-acting agent for the management of type 1 and 2 diabetes mellitus. Drugs 61, 1599\u20131624 (2001).","journal-title":"Drugs"},{"key":"55945_CR15","doi-asserted-by":"publisher","first-page":"643","DOI":"10.4155\/tde.11.19","volume":"2","author":"JA Y\u00e1\u00f1ez","year":"2011","unstructured":"Y\u00e1\u00f1ez, J. A., Remsberg, C. M., Sayre, C. L., Forrest, M. L. & Davies, N. M. Flip-flop pharmacokinetics\u2013delivering a reversal of disposition: challenges and opportunities during drug development. Ther. Deliv. 2, 643\u2013672 (2011).","journal-title":"Ther. Deliv."},{"key":"55945_CR16","doi-asserted-by":"publisher","first-page":"147","DOI":"10.9740\/mhc.2023.06.147","volume":"13","author":"JT Tran","year":"2023","unstructured":"Tran, J. T., Binger, K. J. & Miles, T. M. Assessment of oral overlap with antipsychotic long-acting injectables initiated in an inpatient setting. Ment. Health Clin. 13, 147\u2013151 (2023).","journal-title":"Ment. Health Clin."},{"key":"55945_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-31342-z","volume":"13","author":"MTH Tuhin","year":"2022","unstructured":"Tuhin, M. T. H. et al. Peripherally restricted transthyretin-based delivery system for probes and therapeutics avoiding opioid-related side effects. Nat. Commun. 13, 3590 (2022).","journal-title":"Nat. Commun."},{"key":"55945_CR18","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1038\/nrd2468","volume":"7","author":"J Rautio","year":"2008","unstructured":"Rautio, J. et al. Prodrugs: design and clinical applications. Nat. Rev. Drug Discov. 7, 255\u2013270 (2008).","journal-title":"Nat. Rev. Drug Discov."},{"key":"55945_CR19","doi-asserted-by":"publisher","unstructured":"Scott, C. C., & Robins, E. B. Toxicity of p-Aminobenzoic Acid. Exp. Biol. Med. 49, https:\/\/doi.org\/10.3181\/00379727-49-13507 (1942).","DOI":"10.3181\/00379727-49-13507"},{"key":"55945_CR20","doi-asserted-by":"publisher","first-page":"97ra81","DOI":"10.1126\/scitranslmed.3002473","volume":"3","author":"MM Alhamadsheh","year":"2011","unstructured":"Alhamadsheh, M. M. et al. Potent kinetic stabilizers that prevent transthyretin-mediated cardiomyocyte proteotoxicity. Sci. Transl. Med. 3, 97ra81 (2011).","journal-title":"Sci. Transl. Med."},{"key":"55945_CR21","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/nchembio.281","volume":"6","author":"S Choi","year":"2010","unstructured":"Choi, S., Connelly, S., Reixach, N., Wilson, I. A. & Kelly, J. W. Chemoselective small molecules that covalently modify one lysine in a non-enzyme protein in plasma. Nat. Chem. Biol. 6, 133\u2013139 (2010).","journal-title":"Nat. Chem. Biol."},{"key":"55945_CR22","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1677\/joe.0.1750061","volume":"175","author":"G Schreiber","year":"2002","unstructured":"Schreiber, G. The evolutionary and integrative roles of transthyretin in thyroid hormone homeostasis. J. Endocrinol. 175, 61\u201373 (2002).","journal-title":"J. Endocrinol."},{"key":"55945_CR23","doi-asserted-by":"publisher","first-page":"6481","DOI":"10.1016\/S0021-9258(18)88997-9","volume":"260","author":"J Sundelin","year":"1985","unstructured":"Sundelin, J. et al. The primary structure of rabbit and rat prealbumin and a comparison with the tertiary structure of human prealbumin. J. Biol. Chem. 260, 6481\u20136487 (1985).","journal-title":"J. Biol. Chem."},{"key":"55945_CR24","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1111\/j.1432-1033.1982.tb07051.x","volume":"129","author":"PW Dickson","year":"1982","unstructured":"Dickson, P. W., Howlett, G. J. & Schreiber, G. Metabolism of prealbumin in rats and changes induced by acute inflammation. Eur. J. Biochem. 129, 289\u2013293 (1982).","journal-title":"Eur. J. Biochem."},{"key":"55945_CR25","doi-asserted-by":"publisher","first-page":"91","DOI":"10.2174\/1389200219666180821094502","volume":"20","author":"L Di","year":"2019","unstructured":"Di, L. The impact of carboxylesterases in drug metabolism and pharmacokinetics. Curr. Drug Metab. 20, 91\u2013102 (2019).","journal-title":"Curr. Drug Metab."},{"key":"55945_CR26","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/j.apsb.2018.05.005","volume":"8","author":"D Wang","year":"2018","unstructured":"Wang, D. et al. Human carboxylesterases: a comprehensive review. Acta Pharm. Sin. B 8, 699\u2013712 (2018).","journal-title":"Acta Pharm. Sin. B"},{"key":"55945_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2024.116128","volume":"223","author":"M Nagaoka","year":"2024","unstructured":"Nagaoka, M., Sakai, Y., Nakajima, M. & Fukami, T. Role of carboxylesterase and arylacetamide deacetylase in drug metabolism, physiology, and pathology. Biochem. Pharmacol. 223, 116128 (2024).","journal-title":"Biochem. Pharmacol."},{"key":"55945_CR28","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1007\/s40262-018-0644-7","volume":"57","author":"FM de Man","year":"2018","unstructured":"de Man, F. M., Goey, A. K. L., van Schaik, R. H. N., Mathijssen, R. H. J. & Bins, S. Individualization of Irinotecan Treatment: A Review of Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics. Clin. Pharmacokinet. 57, 1229\u20131254 (2018).","journal-title":"Clin. Pharmacokinet."},{"key":"55945_CR29","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1007\/s13238-017-0437-z","volume":"9","author":"J Lian","year":"2018","unstructured":"Lian, J., Nelson, R. & Lehner, R. Carboxylesterases in lipid metabolism: from mouse to human. Protein Cell 9, 178\u2013195 (2018).","journal-title":"Protein Cell"},{"key":"55945_CR30","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1038\/nsb919","volume":"10","author":"S Bencharit","year":"2003","unstructured":"Bencharit, S., Morton, C. L., Xue, Y., Potter, P. M. & Redinbo, M. R. Structural basis of heroin and cocaine metabolism by a promiscuous human drug-processing enzyme. Nat. Struct. Biol. 10, 349\u2013356 (2003).","journal-title":"Nat. Struct. Biol."},{"key":"55945_CR31","doi-asserted-by":"publisher","unstructured":"Eisner, H. et al. The crystal structure of mouse Ces2c, a potential ortholog of human CES2, shows structural similarities in substrate regulation and product release to human CES1. Int. J. Mol. Sci. 23, https:\/\/doi.org\/10.3390\/ijms232113101 (2022).","DOI":"10.3390\/ijms232113101"},{"key":"55945_CR32","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1038\/nchembio.1907","volume":"11","author":"SC Penchala","year":"2015","unstructured":"Penchala, S. C. et al. A biomimetic approach for enhancing the in vivo half-life of peptides. Nat. Chem. Biol. 11, 793\u2013798 (2015).","journal-title":"Nat. Chem. Biol."},{"key":"55945_CR33","doi-asserted-by":"publisher","first-page":"14876","DOI":"10.1021\/acs.jmedchem.1c01426","volume":"64","author":"F Liu","year":"2021","unstructured":"Liu, F., Ul Amin, T., Liang, D., Park, M. S. & Alhamadsheh, M. M. Enhancing the pharmacokinetic profile of interleukin 2 through site-specific conjugation to a selective small-molecule transthyretin ligand. J. Med. Chem. 64, 14876\u201314886 (2021).","journal-title":"J. Med. Chem."},{"key":"55945_CR34","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s13011-019-0195-4","volume":"14","author":"RB Moss","year":"2019","unstructured":"Moss, R. B. & Carlo, D. J. Higher doses of naloxone are needed in the synthetic opiod era. Subst. Abuse Treat. Prev. Policy 14, 6 (2019).","journal-title":"Subst. Abuse Treat. Prev. Policy"},{"key":"55945_CR35","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S0168-3659(01)00248-6","volume":"73","author":"X Huang","year":"2001","unstructured":"Huang, X. & Brazel, C. S. On the importance and mechanisms of burst release in matrix-controlled drug delivery systems. J. Control. Release 73, 121\u2013136 (2001).","journal-title":"J. Control. Release"},{"key":"55945_CR36","doi-asserted-by":"publisher","unstructured":"Bakhrushina, E. O. et al. Burst release from in situ forming PLGA-based implants: 12 Effectors and ways of correction. Pharmaceutics 16, https:\/\/doi.org\/10.3390\/pharmaceutics16010115 (2024).","DOI":"10.3390\/pharmaceutics16010115"},{"key":"55945_CR37","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.toxlet.2006.05.007","volume":"166","author":"JJ Strandberg","year":"2006","unstructured":"Strandberg, J. J. et al. Toxicological analysis in rats subjected to heroin and morphine overdose. Toxicol. Lett. 166, 11\u201318 (2006).","journal-title":"Toxicol. Lett."},{"key":"55945_CR38","doi-asserted-by":"publisher","first-page":"385","DOI":"10.4155\/fmc.13.215","volume":"6","author":"RS Vardanyan","year":"2014","unstructured":"Vardanyan, R. S. & Hruby, V. J. Fentanyl-related compounds and derivatives: current status and future prospects for pharmaceutical applications. Future Med. Chem. 6, 385\u2013412 (2014).","journal-title":"Future Med. Chem."},{"key":"55945_CR39","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1046\/j.1440-1681.2001.03418.x","volume":"28","author":"SL Borgland","year":"2001","unstructured":"Borgland, S. L. Acute opioid receptor desensitization and tolerance: is there a link? Clin. Exp. Pharmacol. Physiol. 28, 147\u2013154 (2001).","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"key":"55945_CR40","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1124\/pr.111.004598","volume":"63","author":"KM Raehal","year":"2011","unstructured":"Raehal, K. M., Schmid, C. L., Groer, C. E. & Bohn, L. M. Functional selectivity at the \u03bc-opioid receptor: implications for understanding opioid analgesia and tolerance. Pharmacol. Rev. 63, 1001\u20131019 (2011).","journal-title":"Pharmacol. Rev."},{"key":"55945_CR41","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1002\/cpt.2027","volume":"109","author":"MH Algera","year":"2021","unstructured":"Algera, M. H. et al. Tolerance to opioid-induced respiratory depression in chronic high-dose opioid users: A model-based comparison with opioid-na\u00efve individuals. Clin. Pharmacol. Ther. 109, 637\u2013645 (2021).","journal-title":"Clin. Pharmacol. Ther."},{"key":"55945_CR42","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1007\/s00213-022-06125-5","volume":"239","author":"SC Britch","year":"2022","unstructured":"Britch, S. C. & Walsh, S. L. Treatment of opioid overdose: current approaches and recent advances. Psychopharmacology 239, 2063\u20132081 (2022).","journal-title":"Psychopharmacology"},{"key":"55945_CR43","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1007\/s40262-020-00957-0","volume":"60","author":"AK Jones","year":"2021","unstructured":"Jones, A. K., Ngaimisi, E., Gopalakrishnan, M., Young, M. A. & Laffont, C. M. Population pharmacokinetics of a monthly buprenorphine depot injection for the treatment of opioid use disorder: A combined analysis of phase II and phase III trials. Clin. Pharmacokinet. 60, 527\u2013540 (2021).","journal-title":"Clin. Pharmacokinet."},{"key":"55945_CR44","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1007\/s13181-023-00981-z","volume":"20","author":"AI Stolbach","year":"2024","unstructured":"Stolbach, A. I., Mazer-Amirshahi, M., Nelson, L. S. & Cole, J. B. American college of medical toxicology and the American academy of clinical toxicology position statement: Nalmefene should not replace naloxone as the primary opioid antidote at this time. J. Med. Toxicol. 20, 64\u201367 (2024).","journal-title":"J. Med. Toxicol."},{"key":"55945_CR45","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1007\/s00228-015-1884-1","volume":"71","author":"N Donnerstag","year":"2015","unstructured":"Donnerstag, N. et al. Severe opioid withdrawal syndrome after a single dose of nalmefene. Eur. J. Clin. Pharmacol. 71, 1025\u20131026 (2015).","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"55945_CR46","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1080\/20009666.2020.1854417","volume":"11","author":"S Elkattawy","year":"2021","unstructured":"Elkattawy, S., Alyacoub, R., Ejikeme, C., Noori, M. A. M. & Remolina, C. Naloxone induced pulmonary edema. J. Community Hosp. Intern. Med. Perspect. 11, 139\u2013142 (2021).","journal-title":"J. Community Hosp. Intern. Med. Perspect."},{"key":"55945_CR47","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1177\/2042098617744161","volume":"9","author":"R Rzasa Lynn","year":"2018","unstructured":"Rzasa Lynn, R. & Galinkin, J. L. Naloxone dosage for opioid reversal: current evidence and clinical implications. Ther. Adv. Drug Saf. 9, 63\u201388 (2018).","journal-title":"Ther. Adv. Drug Saf."},{"key":"55945_CR48","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/0014-2999(78)90343-6","volume":"51","author":"RA Lahti","year":"1978","unstructured":"Lahti, R. A. & Collins, R. J. Chronic naloxone results in prolonged increases in opiate binding sites in brain. Eur. J. Pharmacol. 51, 185\u2013186 (1978).","journal-title":"Eur. J. Pharmacol."},{"key":"55945_CR49","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1124\/jpet.107.127019","volume":"323","author":"S Sirohi","year":"2007","unstructured":"Sirohi, S., Kumar, P. & Yoburn, B. C. Mu-opioid receptor up-regulation and functional supersensitivity are independent of antagonist efficacy. J. Pharmacol. Exp. Ther. 323, 701\u2013707 (2007).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"55945_CR50","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1007\/s40264-018-0705-8","volume":"41","author":"IA Binswanger","year":"2018","unstructured":"Binswanger, I. A. & Glanz, J. M. Potential risk window for opioid overdose related to treatment with extended-release injectable naltrexone. Drug Saf. 41, 979\u2013980 (2018).","journal-title":"Drug Saf."},{"key":"55945_CR51","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1007\/s40264-020-01020-4","volume":"44","author":"P Jain","year":"2021","unstructured":"Jain, P. et al. Evaluation of opioid overdose reports in patients treated with extended-release naltrexone: Postmarketing data from 2006 to 2018. Drug Saf. 44, 351\u2013359 (2021).","journal-title":"Drug Saf."},{"key":"55945_CR52","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1007\/s12264-013-1406-z","volume":"30","author":"S Jiang","year":"2014","unstructured":"Jiang, S. et al. M1 muscarinic acetylcholine receptor in Alzheimer\u2019s disease. Neurosci. Bull. 30, 295\u2013307 (2014).","journal-title":"Neurosci. Bull."},{"key":"55945_CR53","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.toxlet.2020.02.008","volume":"325","author":"JL Langston","year":"2020","unstructured":"Langston, J. L., Moffett, M. C., Makar, J. R., Burgan, B. M. & Myers, T. M. Carfentanil toxicity in the African green monkey: Therapeutic efficacy of naloxone. Toxicol. Lett. 325, 34\u201342 (2020).","journal-title":"Toxicol. Lett."},{"key":"55945_CR54","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.jsat.2015.10.003","volume":"62","author":"K Alanis-Hirsch","year":"2016","unstructured":"Alanis-Hirsch, K. et al. Extended-release naltrexone: A qualitative analysis of barriers to routine use. J. Subst. Abuse Treat. 62, 68\u201373 (2016).","journal-title":"J. Subst. Abuse Treat."},{"key":"55945_CR55","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1080\/13543784.2023.2187286","volume":"32","author":"S Martinez","year":"2023","unstructured":"Martinez, S. et al. The potential role of opioid vaccines and monoclonal antibodies in the opioid overdose crisis. Expert. Opin. Investig. Drugs 32, 181\u2013185 (2023).","journal-title":"Expert. Opin. Investig. Drugs"},{"key":"55945_CR56","doi-asserted-by":"publisher","first-page":"110","DOI":"10.15585\/mmwr.mm7305a4","volume":"73","author":"ER Payne","year":"2024","unstructured":"Payne, E. R., Stancliff, S., Rowe, K., Christie, J. A. & Dailey, M. W. Comparison of administration of 8-milligram and 4-milligram intranasal naloxone by law enforcement during response to suspected opioid overdose - New York, march 2022-august 2023. Morb. Mortal. Wkly. Rep. 73, 110\u2013113 (2024).","journal-title":"Morb. Mortal. Wkly. Rep."},{"key":"55945_CR57","doi-asserted-by":"publisher","DOI":"10.1186\/s12954-024-00994-z","volume":"21","author":"PM Lemen","year":"2024","unstructured":"Lemen, P. M. et al. High-dose naloxone formulations are not as essential as we thought. Harm. Reduct. J. 21, 93 (2024).","journal-title":"Harm. Reduct. J."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-55945-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-55945-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-55945-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T10:03:57Z","timestamp":1737626637000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-55945-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,23]]},"references-count":57,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["55945"],"URL":"https:\/\/doi.org\/10.1038\/s41467-025-55945-4","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,23]]},"assertion":[{"value":"26 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.M.A. is a cofounder of Eidos Therapeutics and a co-inventor of AG10 (acoramidis, or ATTRuby\u2122), a US FDA-approved drug for the treatment of TTR amyloid cardiomyopathy. M.M.A. has filed, as a sole inventor, a provisional patent application related to the development and application of the new prodrug technology. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"686"}}